Cognition Therapeutics, Inc. (CGTX)

NASDAQ: CGTX · IEX Real-Time Price · USD
1.790
-0.030 (-1.65%)
Mar 28, 2024, 10:39 AM EDT - Market open

Company Description

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.

Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease.

The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial.

Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration.

The company was incorporated in 2007 and is headquartered in Purchase, New York.

Cognition Therapeutics, Inc.
Cognition Therapeutics logo
Country United States
Founded 2007
IPO Date Oct 8, 2021
Industry Biotechnology
Sector Healthcare
Employees 22
CEO Ms. Lisa Ricciardi

Contact Details

Address:
2403 Sidney Street, Suite 261
Pittsburgh, Pennsylvania 15203
United States
Phone 412-481-2210
Website cogrx.com

Stock Details

Ticker Symbol CGTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $12.00
CIK Code 0001455365
CUSIP Number 19243B102
ISIN Number US19243B1026
SIC Code 2836

Key Executives

Name Position
Lisa Ricciardi Chief Executive Officer, President and Director
Dr. Anthony O. Caggiano M.D., Ph.D. Chief Medical Officer and Head of Research & Development
John Brendan Doyle Chief Financial Officer
Dr. Steven A. Weissman Ph.D. Vice President and Head of CMC

Latest SEC Filings

Date Type Title
Mar 26, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 26, 2024 10-K Annual Report
Mar 26, 2024 8-K Current Report
Mar 13, 2024 8-K Current Report
Mar 13, 2024 424B5 Filing
Mar 11, 2024 8-K Current Report
Mar 11, 2024 424B5 Filing
Feb 20, 2024 8-K Current Report
Feb 7, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 19, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals